Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits

Perfusion

Volumn 13, Issue 6, 1998, Pages 419-427

  Baufreton, Christophe ^a,e   Moczar, Madeleine ^b   Intrator, Liliane ^a   Jansen, Piet G M ^c   Te Velthuis, Henk ^d   Le Besnerais, Paul ^a   Farcet, Jean Pierre ^a   Wildevuur, Charles R H ^c   Loisance, Daniel Y ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CNRS   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Dept Pathophysiology Plasma P

^e ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PROTAMINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; CYTOKINE PRODUCTION; EQUIPMENT; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; INFLAMMATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031730153     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919801300605     Document Type: Article

References (30)

1. Edmunds LH. Blood-surface interactions during cardiopulmonary bypass. J Card Surg 1993; 8: 404-10.
2. Wildevuur CRH. Blood damage and activation in cardiopulmonary bypass. In: Friedel N, Hetzer R, Royston D eds. Blood use in cardiac surgery. New York: Springer, 1991: 269-74.
3. Hornick P, George A. Blood contact activation: pathophysiological effects and therapeutic approaches. Perfusion 1996; 11: 3-19.
4. Jansen PGM, te Velthuis H, Huybregts RAJM et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995; 110: 829-34.
5. Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994; 58 421-24.
6. Videm V, Svennevig JL, Fosse E et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.
7. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevvur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
8. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 642-47.
9. Weerwind PW, Maessen JG, van Tits LJH et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995; 110: 1633-41.
10. Steinberg BM, Grossi EA, Schwartz DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 525-29.
11. Moen O, Fosse E, Brockmeier V et al. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg 1995; 60: 1317-23.
12. Ovrum E, Mollnes, TE, Fosse E et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg 1995; 110: 1623-32.
13. Hsu LC. Principles of heparin-coating techniques. Perfusion 1991; 6: 209-19.
14. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Artif Organs 1983; 11: 161-73.
15. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67: 223-28.
16. de Vroege R, Rutten PMMJ, Kalkman C et al. Biocompatibility of three different membrane oxygenators: effects on complement, neutrophil and monocyte activation. Perfusion 1997; 12: 369-75.
17. Jansen PGM, te Velthuis H, Oudemans-Van Straaten HM et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur J Cardiothorac Surg 1994; 8: 125-29.
18. Vukajlovitch SW, Hoffman J, Morrison DC. Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathway. Mol Immunol 1987; 24: 319-32.
19. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 1008-16.
20. Menasché P, Haydar S, Peynet J et al. A potential mechanism of vasodilation after warm heart surgery. The temperature-dependant release of cytokines. J Thorac Cardiovasc Surg 1994; 107: 293-99.
21. Frering B, Philip I, Dehoux M, Rolland C, Langlois JM, Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 636-41.
22. Deng MC, Wiedner M, Erren M, Möllhoff T, Assmann G, Scheld HH. Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics. Eur J Cardiothorac Surg 1995; 9: 22-9.
23. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993; 56: S92-96.
24. Hennein HA, Ebba H, Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108: 626-35.
25. Menasché P, Peynet J. Haeffner-Cavaillon N et al. Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass. Circulation 1995; 92(suppl II): II334-II340.
26. Boonstra PW, van Imhoff GW, Eijsman L et al. Reduced platelet activation and improved hemostasis after controlled cardiotomy suction during clinical membrane oxygenator perfusions. J Thorac Cardiovasc Surg 1985; 89: 900-90.
27. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 828-33.
28. Le Deist F, Menasché P, Kucharski C, Bel A, Piwnica A, Bloch G. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. A clinical study. Circulation 1995; 92: 354-58.
29. Boldt J, Osmer C, Schindler E, Linke LC, Stertmann WA, Hempelmann G. Circulating adhesion molecules in cardiac operations: influence of high-dose aprotinin. Ann Thorac Surg 1995; 59: 100-105.
30. Ashraf S, Tian Y, Cowan D et al. 'Low-dose' aprotinin modifies hemostasis but not proinflammatory response. AnnThorac Surg 1997; 63: 68-73.